Douglas T. Dieterich

Dr. Douglas T. Dieterich


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2014 in JAMA
Verified
Journal Article
Open access
PDF file
MSMark S. Sulkowski
Mark S. Sulkowski
SNSusanna Naggie
Susanna Naggie
JLJacob Lalezari
Jacob Lalezari
WFW. Jeffrey Fessel
W. Jeffrey Fessel
KMKaram Mounzer
Karam Mounzer
FIfor the PHOTON-1 Investigators
for the PHOTON-1 Investigators
Up to 7 million persons worldwide are infected with both human immunodeficiency virus (HIV) and hepatitis C virus (HCV).1 Human immunodeficiency virus and HCV coinfection is associated with high rates of liver fibrosis, cirrhosis, hepatocellular carcinoma, and overall mortality.2 Coinfected patients who are cured of HCV have improved clinical outcomes and survival.3

5 September 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DDDouglas T. Dieterich
Douglas T. Dieterich
JRJürgen Kurt Rockstroh
Jürgen Kurt Rockstroh
COChloe Orkin
Chloe Orkin
FGFélix Gutiérrez
Félix Gutiérrez
MKMarina Klein
Marina Klein
WJWolfgang Jessner
Wolfgang Jessner
Background. Simeprevir is an oral, once-daily, hepatitis C virus (HCV) NS3/4A protease inhibitor for the treatment of chronic HCV genotype 1 infection. Human immunodeficiency virus (HIV) coinfection accelerates progression of liver disease. This uncontrolled, open-label trial explored the safety and efficacy of simeprevir in patients with HCV genotype 1/HIV type 1 (HIV-1) coinfection. Methods. Patients received simeprevir (150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks. Noncirrhotic HCV treatment-naive patients and prior relapsers received response-guided therapy (RGT) with peg-IFN/RBV for 24 or 48 weeks. Prior null responders, prior partial responders, and patients with cirrhosis received peg-IFN/RBV for 48 weeks. The primary endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12). Results. One hundred and six patients (93 on antiretroviral therapy) were enrolled and treated. SVR12 rates were 79.2% in HCV treatment-naive patients, 57.1% in prior null responders, 86.7% in prior relapsers, and 70.0% in prior partial responders. Fifty-four of 61 eligible patients (88.5%) met RGT criteria for 24 weeks of peg-IFN/RBV, of whom 87.0% (47/54) achieved SVR12. SVR12 rates were 80.0% (36/45) and 63.6% (14/22) for patients with METAVIR scores of F0–F2 and F3–F4, respectively. Common adverse event (AE) rates were consistent with peg-IFN/RBV therapy (fatigue, headache, nausea, neutropenia). Most AEs were grade 1/2; serious AEs occurred in 5.7% of patients, none of which were fatal. Conclusions. Simeprevir was generally well tolerated with safety similar to that observed in HCV-monoinfected patients and high SVR12 rates in HCV treatment-naive patients, prior relapsers, prior partial responders, and prior null responders with HIV-1 coinfection. Clinical Trials Registration. NCT01479868.

28 July 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
KBKian Bichoupan
Kian Bichoupan
VMValerie Martel-Laferriere
Valerie Martel-Laferriere
DSDavid Sachs
David Sachs
MNMichel Ng
Michel Ng
ESEmily A. Schonfeld
Emily A. Schonfeld
ABAndrea D. Branch
Andrea D. Branch
In registration trials, triple therapy with telaprevir (TVR), pegylated interferon (Peg-IFN), and ribavirin (RBV) achieved sustained virological response (SVR) rates between 64% and 75%, but the clinical effectiveness and economic burdens of this treatment in real-world practice remain to be determined. Records of 147 patients who initiated TVR-based triple therapy at the Mount Sinai Medical Center (May-December 2011) were reviewed. Direct medical costs for pretreatment, on-treatment, and posttreatment care were calculated using data from Medicare reimbursement databases, RED Book, and the Healthcare Cost and Utilization Project database. Costs are presented in 2012 U.S. dollars. SVR (undetectable hepatitis C virus [HCV] RNA 24 weeks after the end of treatment) was determined on an intention-to-treat basis. Cost per SVR was calculated by dividing the median cost by the SVR rate. Median age of the 147 patients was 56 years (interquartile range [IQR] = 51–61), 68% were male, 19% were black, 11% had human immunodeficiency virus/HCV coinfection, 36% had advanced fibrosis/cirrhosis (FIB-4 scores ≥3.25), and 44% achieved an SVR. The total cost of care was $11.56 million. Median cost of care was $83,721 per patient (IQR = $66,652-$98,102). The median cost per SVR was $189,338 (IQR = $150,735-$221,860). Total costs were TVR (61%), IFN (24%), RBV (4%), adverse event management (8%), professional fees (2%), and laboratory tests (1%). Conclusions: TVR and Peg-IFN accounted for 85% of costs. Pharmaceutical prices and the low (44%) SVR rate, in this real-world study, were major contributors to the high cost per SVR. (Hepatology 2014;60:1187–1195)

18 April 2023 in Viruses
Verified
Journal Article
Open access
PDF file
YLYoung-Suk Lim
Young-Suk Lim
WKW. Ray Kim
W. Ray Kim
DDDouglas T. Dieterich
Douglas T. Dieterich
JKJia-Horng Kao
Jia-Horng Kao
JFJohn Flaherty
John Flaherty
PKPatrick T.F. Kennedy
Patrick T.F. Kennedy
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage. This contrasts with hepatitis C or HIV where early treatment is recommended in all infected patients, regardless of end-organ damage. This narrative review aims to provide an overview of data on the early initiation of antiviral treatment and its related potential economic impact. Literature searches were performed using PubMed and abstracts from international liver congresses (2019–2021). Data on risk of disease progression and HCC and the impact of antiviral treatment in currently ineligible patients were summarized. Cost-effectiveness data on early antiviral treatment initiation were also collated. Accumulating molecular, clinical, and economic data suggest that early initiation of antiviral treatment could save many lives through HCC prevention in a highly cost-effective manner. In light of these data, we consider several alternative expanded treatment strategies that might further a simplified ‘treatment as prevention’ approach.

14 October 2022 in Gastro Hep Advances
Verified
Journal Article
Open access
DDDouglas T. Dieterich
Douglas T. Dieterich
CGCamilla Graham
Camilla Graham
SWSu Wang
Su Wang
PKPaul Kwo
Paul Kwo
YLYoung-Suk Lim
Young-Suk Lim
MSMark Sulkowski
Mark Sulkowski
Hepatitis B virus (HBV) infection continues to threaten millions of lives across the globe, despite universal vaccination efforts. Current guidelines for screening, vaccination, and treatment are complex and have left too many people undiagnosed or improperly managed. Antiviral therapy has been shown to significantly reduce the incidence of liver-related complications, including liver cancer. However, the complexity of existing guidelines can make it difficult to identify which patients to target for treatment, and recommendations that are difficult to implement in real-world settings pose a barrier to eligible patients to receive therapy and contribute to health disparities in HBV care. The goal of this global expert panel was to gain consensus on a streamlined approach to HBV care to facilitate implementation of HBV intervention and treatment, especially in the primary care setting. A group of 8 liver and infectious disease specialists attended a meeting in January 2021 with the objective of gaining consensus on a streamlined algorithm for HBV care that would encourage implementation of HBV intervention and treatment. We have created a comprehensive perspective highlighting screening optimization, diagnostic workup, treatment, and monitoring. This treatment algorithm is designed to provide a streamlined visual pathway for risk stratification and management of patients with HBV that can be adapted in various care settings. Simplification of guidelines will be critical to achieving health equity to address this public health threat and achieve HBV elimination.

1 December 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
BDBen L. Da
Ben L. Da
GEGhideon Ezaz
Ghideon Ezaz
TKTatyana Kushner
Tatyana Kushner
JCJames Crismale
James Crismale
GKGaurav Kakked
Gaurav Kakked
BSBehnam Saberi
Behnam Saberi
Despite an increase in the number of liver transplants (LTs) performed in the United States, the rate at which patients are placed on the waitlist continues to surpass the increased number of transplants, creating a significant mismatch between organ supply and demand.1 The use of hepatitis C virus (HCV)–positive organs has been widely adopted as one of the solutions to the major organ shortage by increasing the donor pool.2 Although HCV infection is estimated to affect 1% to 2% of the general US population, this risk is higher (3%-18%) among organ donors with increased risk as defined by the Public Health Service.3 In light of the ongoing opioid epidemic and the associated rise in drug overdose deaths, the number of Public Health Service “increased risk” HCV-positive organs available has been increasing rapidly.4,5